1-8 of 8
Hina Jolin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial

Pankit Vachhani, Tsewang Tashi, Gary J. Schiller, Stephanie Lee, Miguel Piris Villaespesa, Helena Pomares, Cristina Bulai Livideanu, Jonathan Lambert, Anthony M. Hunter, Tracy I. George, Cristina Papayannidis, Khalid Shoumariyeh, Rita Petroro, Jenna Zhang, Amanda Pilla, Hina Jolin, Rachael Easton, Vinod Pullarkat
Journal: Blood
Blood (2023) 142 (Supplement 1): 4567.
https://doi.org/10.1182/blood-2023-178885
Published: 2023
Journal Articles

Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Prithviraj Bose, Stephen T. Oh, Brian Modena, Anthony M. Hunter, Cem Akin, Mariana Castells, Michael Manning, Richard Herrscher, Frank Siebenhaar, Daniel J. DeAngelo, Tracy I. George, Benjamin Exter, Jenna Zhang, Amanda Pilla, Hina Jolin, Rachael Easton, Lindsay A.M Rein
Journal: Blood
Blood (2023) 142 (Supplement 1): 77.
https://doi.org/10.1182/blood-2023-178927
Published: 2023
Journal Articles

A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM)

Jason Gotlib, Tracy I. George, Michael W. Deininger, Tsewang Tashi, Vinod A. Pullarkat, Prithviraj Bose, Francis Payumo, Amanda Pilla, Hina Jolin, Jessica Sachs, Daniel J. DeAngelo
Journal: Blood
Blood (2021) 138 (Supplement 1): 3636.
https://doi.org/10.1182/blood-2021-145928
Published: 2021
Journal Articles

A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Frank Siebenhaar, Jason Gotlib, Michael W. Deininger, Daniel J. DeAngelo, Francis Payumo, George Mensing, Hina Jolin, Jessica Sachs, Tracy I. George
Journal: Blood
Blood (2021) 138 (Supplement 1): 3642.
https://doi.org/10.1182/blood-2021-147072
Published: 2021
Journal Articles

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

Joseph M. Connors, MD, Anas Younes, MD, Andrea Gallamini, MD, Stephen M. Ansell, MD PhD, Won-Seog Kim, Ranjana H Advani, MD, Nancy L. Bartlett, MD, David J. Straus, MD, Anna Sureda, MD, Martin Hutchings, MD PhD, Monika Dlugosz-Danecka, MD PhD, Gerald Engley, PharmD, Keenan Fenton, Rachael Liu, PhD, Harry Miao, MD, Hina Jolin, Pharm D, Ashish Gautam, PhD MBA, John Radford, MD FRCP
Journal: Blood
Blood (2018) 132 (Supplement 1): 2904.
https://doi.org/10.1182/blood-2018-99-118828
Published: 2018
Journal Articles

Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study

Howland E. Crosswell, MD, Ann S. LaCasce, MD MSc, Nancy L. Bartlett, MD, David J. Straus, MD, Kerry J Savage, BSc, MD MSc, Keenan Fenton, Gerald Engley, PharmD, Hina Jolin, Pharm D, Rachael Liu, PhD, Pier Luigi Zinzani, MD, Graham P. Collins, MB BS DPhil, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1647.
https://doi.org/10.1182/blood-2018-99-112907
Published: 2018
Journal Articles

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Andrew M. Evens, DO, MSc, Joseph M. Connors, MD, Anas Younes, MD, Stephen M. Ansell, MD PhD, Won Seog Kim, MD PhD, John Radford, MD FRCP, Tatyana A. Feldman, MD, Joseph Tuscano, Kerry J Savage, BSc, MD MSc, Yasuhiro Oki, MD, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, Christopher Pocock, MD PhD, Monika Dlugosz-Danecka, MD PhD, Keenan Fenton, Gerald Engley, PharmD, Rachael Liu, PhD, Harry Miao, MD, Hina Jolin, Pharm D, Ashish Gautam, PhD MBA, Andrea Gallamini, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1618.
https://doi.org/10.1182/blood-2018-99-112178
Published: 2018
Journal Articles

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

Joseph M Connors, MD, Wojciech Jurczak, PhDMD, David J. Straus, MD, Stephen M Ansell, MD PhD, Won Seog Kim, MD, Ph. D., Andrea Gallamini, MD, Anas Younes, MD, Sergei Alekseev, PhD, Arpad Illes, MD, Marco Picardi, Ewa Lech-Maranda, MDPhD, Yasuhiro Oki, MD, Tatyana A Feldman, MD, Piotr Smolewski, MD PhD, Kerry J Savage, BSc, MD MSc, Nancy L. Bartlett, MD, Jan Walewski, MD PhD, Robert W. Chen, MD, Rod Ramchandren, MD, Pier Luigi Zinzani, MD, David Cunningham, MD FRCP, Dae Seog Heo, MD, Andras Rosta, MD, Neil Josephson, MD, Katherine L. Ruffner, MD, Jessica Sachs, Rachael Liu, PhD, Hina Jolin, Pharm D, Dirk Huebner, MD, John A. Radford, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 6.
https://doi.org/10.1182/blood.V130.Suppl_1.6.6
Published: 2017